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1. ABSTRACT
Telomeres are highly regulated and dynamic 
complexes that protect the genomic DNA and prevent the 
end of linear chromosomes from being misrecognized 
as a broken DNA. Due to the end replication problem, 
telomeres of somatic cells shorten with each cell division, 
inducing cell senescence. Telomerase is a reverse 
transcriptase capable of compensating telomere attrition 
by adding telomere repeats to the ends of chromosomes. 
Human telomeres are associated with the shelterin 
complex which consists of six telomere-associated 
proteins that specifically bind to telomeric DNA. Alterations 
or removal of individual shelterin components would 
lead to telomere uncapping and telomere dysfunction, 
resulting in cellular senescence and transformation to 
a malignant state. Another complex of multifunctional 
proteins, named non-shelterin complex, is thought to 
prevent telomere degradation and facilitate telomerase-
based telomere elongation. As telomerase is highly 
expressed in most human tumor cells, it is considered 
an attractive target for new therapeutic strategies. In 
this review, we will summarize the characteristics of 
telomeres and telomerase in lymphoid malignancies and 
discuss the role of telomere-associated proteins in these 
entities.
2. INTRODUCTION
2.1. Telomeres and telomerase
Telomeres are highly regulated and dynamic 
complexes at chromosome ends, consisting in human 
cells of tandem repeats of the sequence TTAGGG 
and associated protective proteins (1). The main 
role of telomeres is to protect the genomic DNA and 
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prevent the end of linear chromosomes from being 
misrecognized as a broken DNA. As known, due to the 
end-replication problem, the DNA replication machinery 
cannot completely copy the DNA of linear chromosomes, 
leading to telomeres progressively shorter with repeated 
cell division.
In eukaryotes, this deficiency can be resolved 
by the cellular ribonucleoprotein enzyme telomerase, 
which can add telomeric repeat sequences to the ends of 
chromosomes, thus elongating them to compensate for 
their attrition (2). The core of the telomerase holoenzyme 
complex consists of the catalytic reverse transcriptase 
(TERT) subunit, the RNA template (TERC) and dyskerin 
(DKC1) (3). Most normal human cells lack sufficient levels 
of telomerase to maintain telomere length (TL), hence 
telomeres shorten over time and result in replicative 
senescence (4). By contrast, in most human tumor cells 
telomerase is highly expressed, and TL is maintained (5). 
Approximately 10% to 15% of human cancers lack 
detectable telomerase activity and the mechanism for 
maintaining the lengths of telomeres is referred to as 
alternative lengthening of telomere (ALT). Defects in the 
protection of telomeres have been implicated in cancer 
and aging (6).
Despite their heterochromatic state, telomeres 
are transcribed giving rise to long non-coding RNAs 
(lncRNA) called TERRA (telomeric repeat-containing 
RNA). TERRA molecules play critical roles in telomere 
biology, including regulation of telomerase activity, 
heterochromatin formation at chromosome ends and 
capping of telomeres. Nevertheless, the mechanisms of 
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action of telomeric non-coding RNAs remain largely to be 
elucidated (7).
2.2. Shelterin and non-shelterin complexes
Human telomeres are associated with the 
shelterin complex, which contains six proteins: TRF1, 
TRF2, POT1, TIN2, TPP1 and RAP1. Among them, 
TRF1 and TRF2 (Telomeric Repeat Binding Factor 
1 and 2) are homodimeric proteins that bind to the 
double-stranded telomeric DNA. Several in vitro studies 
have suggested a DNA remodeling role for TRF1 and 
TRF2 (8, 9). POT1 (Protection Of Telomeres 1) binds 
specifically to single-stranded telomeric DNA and forms 
a heterodimer with TPP1 (ACD gene: Adrenocortical 
Dysplasia Homolog) protein (10). TIN2 (TRF1-Interacting 
Protein 2) is a hub that interacts with TRF1, TRF2, and 
POT1/TPP1 (10, 11), mediating the assembly of the 
entire complex. RAP1 (Repressor/Activator Protein 1) is 
recruited through its interaction with TRF2 (9). Alterations 
or removal of individual shelterin subunits leads to severe 
telomere uncapping, which triggers specific DNA damage 
response (DDR) pathways as they are recognized as 
double-strand breaks. For instance, TRF1 was shown 
to prevent the activation of both ataxia telangiectasia 
mutated (ATM) and ataxia telangiectasia and Rad3 
related (ATR) pathways (12). In addition, TRF2, RAP1, 
and POT1/TPP1 were shown to inhibit the activation of 
ATM (13), homology-directed recombination (14), and 
ATR (15) pathways, respectively.
A current model for how telomere shortening 
activates a DDR suggests that critically short telomeres 
would fail to recruit the shelterin amount required 
for repressing the DNA repair pathways (16). On the 
contrary, long telomeres recruit more TRF1 and TRF2, 
facilitating the t-loop formation. In the t-loop state, 
telomerase would no longer be able to elongate the 
chromosome ends, leading to loss of sequences with 
successive cell divisions. In agreement with this model, 
Takai et al (17) have shown that short telomeres serve 
as a better substrate for telomerase than long telomeres, 
creating a feedback mechanism to maintain the TL. As 
telomeres gradually shorten, they switch to an open 
state due to a lower number of shelterin subunits. At 
this stage, the telomere elongation would again take 
place, preventing complete loss of the telomeric DNA 
and resulting in the stabilization of the telomeres at a 
short length.
Another complex of multifunctional proteins, 
named the non-shelterin complex, comprise a set of 
multifunctional factors such as DNA repair proteins 
MRE11/NBS/RAD50 (MNR complex) and Replication 
Protein A1 (RPA1) that prevent telomere degradation and 
facilitate telomerase-based telomere elongation (18). 
Maintenance of the telomere architecture involves a 
highly regulated network of protein-protein, protein-DNA 
and protein-RNA interactions; thus its impairment can 
result in telomere dysfunction, cellular senescence and 
transformation to a malignant state (14, 19).
In addition, there is another complex, named 
ribonucleoprotein (RNP) complex, composed of four 
evolutionarily conserved proteins, DKC1, NHP2 (NHP2 
ribonucleoprotein), NOP10 (NP10 ribonucleoprotein), 
and GAR1 (GAR1 ribonucleoprotein), and a function-
specifying, noncoding H/ACA RNAs (20, 21). DKC1, 
NHP2 and NOP10 form a trimer that bound directly to 
H/ACA small nucleolar (sno)/small Cajal body-specific 
(sca) RNAs (sno/scaRNA) and the 3´ domain of 
TERC (22, 23). H/ACA RNPs contribute to telomerase 
assembly and stabilization, and posttranscriptional 
processing of nascent ribosomal RNA and spliceosomal 
RNA (24-26). DKC1, NHP2 and NOP10 are 
interdependent of each other for stability (27); the loss of 
function of any of these proteins reduces TERC stability 
and decreases telomerase activity. On the contrary, GAR1 
binds only to DKC1 and is needed for proper functioning 
of the H/ACA RNPs (28). In a recent report, von Stedingk 
et al (29) suggests that at early tumor stage cells with 
low DKC1, NHP2 and GAR1 expression levels may 
undergo genetic alterations and instability associated 
to telomere dysfunction. However, at advanced stage, 
over-expression of H/ACA RNP components, associated 
to increased telomerase activity, would favor tumor 
progression.
Several studies using genetically modified mice 
for different components of the telomere complexes 
suggest a role for these proteins in cancer susceptibility 
and age-related diseases even in the presence of normal 
telomerase activity and normal TL (30-32). Telomere 
dynamics have been extensively studied in hematologic 
malignancies. In this review we will consider the current 
evidence for the role of telomere-associated proteins in 
lymphoid neoplasm.
3. TELOMERE HOMEOSTASIS IN LYMPHOID 
MALIGNANCIES
3.1. Chronic lymphocytic leukemia (CLL)
CLL is the most common type of adult leukemia 
in the Western world, representing about 30% of all 
leukemias; the disease mainly affects individuals 
>60 years of age. It is characterized by the accumulation 
of small B lymphocytes with a mature appearance in 
blood, bone marrow, lymph nodes and other lymphoid 
tissues (33). It is a heterogeneous disorder with a highly 
variable clinical course, with time to progression ranging 
from months to decades. In the last years several 
prognostic biomarkers, including genomic alterations 
and mutational status of IGHV (immunoglobulin 
heavy chain variable) region, have been identified, 
allowing the subdivision of CLL into clinical relevant 
subgroups (34-37). More recently, advances in molecular 
and genetic profiling have led to the ability to identify 
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sub-groups of patients with CLL whose disease may 
respond to selected therapy (38).
In CLL, average TL has been reported as an 
emerging prognostic factor. In general, the TLs of B-CLL 
cells are significantly shorter than those from B cells of 
age-matched normal controls (39-43). Short telomeres 
have been associated with genetic complexity and a high 
risk of genomic aberrations (40, 42, 44), and ultimately 
implicated in disease outcome (42, 44, 45). Besides, an 
association between short TL and a large of copy number 
aberrations detected by high resolution SNP-arrays was 
described (45).
Furthermore, the TLs of unmutated (UM) CLL 
cases, associated to poor outcome, are much shorter 
than those of age-matched normal donors, and they are 
even shorter than those of the mutated (M) cases, related 
to a better prognosis (39-42, 44-46). Studies of our group 
support these findings, showing short TL in UM-CLL 
patients compared to both M-CLL cases and normal 
controls, with significant differences with respect to the 
last group (Figure 1). Besides shortened TL, telomere 
fusion and genomic instability was also observed in 
patients with CLL (47). We have recently found that 
CLL patients with two or more chromosome aberrations 
displayed a significant TL reduction (Figure 2) and 
more importantly shorter treatment free survival when 
compared to cases with one or no anomalies (43). These 
findings indicate the importance of telomere dysfunction 
in driving genomic instability. In this regard, Lin et al (47) 
showed that a subset of early-stage patients exhibited 
extensive telomere erosion and fusion, indicating that 
telomere shortening and dysfunction may be critical in 
the progression of the disease.
Increased telomerase expression and activity 
were also observed in CLL patients (Table 1). Some 
studies proved that patients expressing TERT have 
significantly shorter survival than TERT-negative cases, 
regardless of disease stage (42, 48-50). In addition, the 
levels of TERT expression were significantly increased 
in advanced CLL stages and, within all stages, in the 
clinically aggressive UM-CLL cases. However, this 
relationship was not seen by Damle et al (51) in blood-
derived CLL cells grouped as a whole, although high 
telomerase activity was found in the poor outcome, 
UM-CLL subgroup. In addition, a recent report (52) did 
not find significant association between TERT expression 
and the most important prognostic factors of CLL as well 
as clinical outcome. Thus, studies in larger series of 
CLL patients will be necessary to clarify the prognostic 
significance of TERT expression in this pathology.
Altered expression of telomere-associated 
proteins has also been reported in this entity (Table 1). 
Poncet et al (53) have carried out transcriptomic analysis 
of telomerase components, shelterin proteins and a set 
of non-shelterin proteins. They found that the mRNA 
levels are lower in CLL cells for TRF1 and RAP1, slightly 
reduced for TRF2, and almost unchanged for TIN2. 
A decrease in mRNA levels of KU80, MRE11, and RAD50 
and an increase in RPA1 were also observed. These 
findings suggest that the capping complex might be 
disrupted, facilitating telomere reduction independently 
of telomerase levels. In agreement with this hypothesis, 
Augereau et al (54) have shown that shelterin 
Figure 1.Telomere length in mutated (M)-IGHV and unmutated (UM)-
IGHV chronic lymphocytic leukemia patients and normal controls (NC).
Figure 2. Telomere length in genetic risk groups of chronic lymphocytic 
leukemia patients and controls. *Significant differences with respect to 
del11q/17p, +12 and chromosome abnormalities groups (p<0.0.001). 
NA: No alterations.
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deregulation correlates with the presence of telomere 
damage-induced foci (TIF) in early stages of CLL. Since 
the presence of TIF is a hallmark of senescent cells (55), 
Augereau et al (54) propose that early stage CLL is 
associated to accelerated B lymphocyte senescence. 
This might result from the accumulation of various 
telomere dysfunctions in the B cell lineage, including 
telomerase and shelterin down-regulation (53, 54). On 
the contrary, Hohxa et al (52) studying untreated CLL 
patients at early clinical stage by microarrays, found a 
significant increased expression for POT1, TRF1 and 
RAP1, meanwhile no differences were observed for TRF2, 
TPP1 and TIN2. The analysis of non-shelterin genes also 
showed a significant up-regulation for MRE11A, RAD50 
and RPA1 as compared with controls, but no statistically 
difference was observed for NBS. Although these results 
need to be confirmed at the protein level, they suggest 
that modulation of telomere-associated genes, together 
with telomere shortening, represent an early event in 
CLL. Simultaneously, Véronèse et al (56) performed 
an unsupervised hierarchical clustering analysis based 
on the combination of cytogenetics and telomeric 
characteristics. This study allowed the subdivision of 
patients in three different clusters, in which cluster 
I -associated to good prognosis parameters- showed 
long telomeres and high expression of TRF1, TRF2 and 
POT1 genes. On the contrary, patients from clusters II 
and III, related to poor prognostic features, had a striking 
decrease in TL and gene-expression levels, suggesting 
a relationship between high risk cytogenetic alterations 
and severe telomere and chromosome instability. 
Discrepancies among data of the literature may be related 
with the particular characteristics of series studied and/or 
the number of patients analyzed. Interestingly, Ramsay 
et al (57) found somatic mutations in POT1 gene in 
3.5% of all CLL cases, occurring exclusively in clinically 
aggressive CLL patients with UM-IGHV status. POT1-
mutated CLL cells showed high frequency of telomeric 
and chromosomal abnormalities, suggesting mutations 
of this gene favor the acquisition of malignant features 
of leukemic cells and, that they likely represent driver 
mutations in this pathology. Thus, POT1 appear as the 
first component of the telomere shelterin complex found 
to be mutated in human cancer. In addition, within the 
Table 1. Expression profiles of telomere-associated genes in lymphoid malignancies
Lymphoid 
malignancy
Expression profile when compared to controls
Shelterin Non-shelterin Telomerase complex
Upregulated Downregulated Unchanged Upregulated Downregulated Unchanged Upregulated Downregulated
CLL TRF152 TRF153 TRF252 MRE1152 RAD5053 NBS52 TERT48,52 TERT53
POT152 TRF253 TPP152 RAD5052 MRE1153 DKC153
RAP152 RAP153 TIN252,53 RPA152,53 Ku8053
BL TRF277  TRF177 PIF77  Tankyrase77 TERT77  
FL   TRF177   Tankyrase77  TERT77
TRF277 PIF77
DLBCL   TRF177   Tankyrase77  TERT77
TRF277 PIF77
MCL TRF180  TRF177   Tankyrase77 TERT80 TERT77
TRF280 TRF277 PIF77 DKC180
POT180
TIN280
TPP180
RAP180
Plasma cell 
disorders
TRF294,96 TRF194  MRE1197   TERT94,96,97  
POT180 RAD5097 DKC197
TIN280 NBS97
TPP180 RPA197
RAP180 Tankyrase94
CLL: Chronic lymphocytic leukemia; BL: Burkitt’s lymphoma; FL: Follicular lymphoma; DLBCL: Diffuse large B cell lymphoma; MCL: Mantle cell 
lymphoma
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shelterin complex, ACD is required for POT1 to perform 
its role in protecting telomeres from being recognized 
as DNA damage (58, 59); this subunit is also necessary 
for the recruitment of telomerase to telomeres (60, 61). 
Recent studies found ACD mutations in patients with 
childhood pre-B acute lymphoblastic leukemia (62) 
and inherited bone marrow failure (63). These findings 
indicate the importance of mutations in telomere-
associated genes as a disease-causing in humans and 
support the hypothesis that telomere dysfunction results 
in genomic rearrangements that may prone cancer 
initiation and progression (64).
Finally, the H/ACA RNP complex was scarcely 
studied in lymphoid malignancies. In CLL, Ronchetti 
et al (65) explored the expression profile of snoRNAs 
and scaRNAs associated to the H/ACA RNP complex 
in a series of Binet stage A CLL patients. This study 
could define two subgroups of patients, one with low 
expression of SNORA74A and SNORD116-18 associated 
to better prognosis and the other characterized by the 
high expression of at least one of the two snoRNAs, 
related to a high risk disease. These findings support 
a possible role of non-coding RNA deregulation in the 
prognosis of CLL as well as its potential useful to predict 
the clinical outcome of early stage patients. In addition, 
as previously referred, there are four proteins associated 
to H/ACA RNP complex (DKC1, NOP10, NHP2 and 
GAR1). To our knowledge, there is only one report in the 
literature that analyzed DKC1 expression in CLL (53), 
detecting a significant reduced transcription level of 
this gene. Preliminary results of our group showed a 
global deregulation of DKC1, NOP10, NHP2 and GAR1 
genes compared to normal controls (data not shown). 
Its association with a high number of genetic alterations 
and UM-IGHV mutational status suggests a role for these 
telomere-associated genes in genomic instability and 
telomere dysfunction in CLL.
3.2. B-cell malignant lymphomas
Non-Hodgkin lymphomas (NHL) comprises 
a group of closely related heterogeneous diseases 
derived from malignant transformation of lymphoid 
cells, characterized by distinctive morphologic, 
immunophenotypic, genetic and clinical features. They 
are clonal tumours of mature and immature B, T or natural 
killer cells at various stages of differentiation, that show 
variable clinical behavior ranging from highly aggressive 
to an indolent course. Among them, B-cell neoplasms 
include numerous histological subtypes that correspond 
approximately to 90% of all NHL cases (66).
Telomere reduction was vastly studied in B-cell 
lymphomas. In general, mantle cell lymphoma (MCL) and 
CLL display the shortest TLs, whereas follicular lymphoma 
(FL) and diffuse large B cell lymphoma (DLBCL) show the 
longest TL (67, 68). Studies performed by our group in 
MCL, DLBCL and FL (69, 70) showed comparable results 
as those reported by Walsh et al (68). However, the 
shortest telomeres were observed in DLBCL secondary 
to FL, a very aggressive subtype not studied in other 
series, supporting the participation of telomere shortening 
as other genetic change involved in the transformation 
process (69). In reference to MCL, our study and data 
of the literature (70, 71) showed that TL reduction in this 
pathology is independent of the clinical characteristics, 
morphology and karyotype and, as opposed to CLL, did 
not reveal any prognostic relevance.
Several publications were reported on 
telomerase activity in B-cell malignant lymphomas. In 
these studies, increased telomerase activity was found 
in patients with Hodgkin disease compared to reactive 
lymph nodes (72, 73). Furthermore, a positive correlation 
of telomerase activity with the rate of proliferation in 
different subtypes of B-cell NHLs as well as lymphoid cell 
lines was observed (74-76). In contrast to these studies, 
Klapper et al (77) found similar telomerase activity and 
TERT expression in patients with MCL, FL and DLBCL, 
when compared to normal lymph nodes (Table 1). In 
addition, Burkitt’s lymphoma was the only subtype that 
showed significantly higher telomerase activity and TERT 
expression, which expressed approximately 17 times 
the activity found in the other entities. A more recent 
report, found that B-cell malignancies with translocations 
affecting the locus 5p13.3.3, in which TERT gene is 
located, showed higher transcriptional expression of 
this gene as well as increased telomerase activity. 
These findings suggest a role of these chromosomal 
abnormalities in TERT deregulation and its possible 
contribution to lymphomagenesis (78). As for MCL, 
contradictory results have been observed for telomerase 
activity and expression (Table 1). Trentin et al (79) 
detected increased activity levels in five leukemic MCL 
cases, whereas Klapper et al (77) found low levels 
of telomerase activity in association with low TERT 
expression in patients compared to normal lymph 
nodes. In a recent study of our group (80), we identified 
somatic mutations in the TERT promoter (TERTp) region, 
upstream of the ATG start site, that were associated with 
higher TERT mRNA expression in MCL cells. Somatic 
mutations in the TERTp region were detected in many 
solid tumors (81-83). Different authors (84, 85) had 
previously demonstrated that these mutations generate 
de novo consensus binding motifs for E-twenty-six (ETS) 
transcription factors, and in in vitro reporter assays, the 
mutations increased transcriptional activity from the TERT 
promoter by two- to fourfold. In our study, the upregulation 
of TERT caused by TERTp mutations appeared to 
influence molecular, cellular, and clinical behavior of MCL. 
This is explained by the observation that most of TERTp-
mutant MCL showed UM or minimally M IGHV status, 
overexpressed the transcription factor SOX11 (SRY 
(Sex Determining Region Y)-box 11) -associated with 
adverse prognosis- and displayed altered expression of 
telomere-associated genes. Thus, our findings suggest 
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an important role of these mutations as a driver event in 
MCL development and maintenance.
In addition, the expression of shelterin and 
non-shelterin subunits was scarcely evaluated in NHLs 
(Table 1). TRF1 as well as Tankyrase, an inhibitor 
of TRF1, did not show significant differences in their 
expression levels among all tissues examined, including 
Burkitt’s lymphoma. However, transcript levels of TRF2 
and the helicase PIF1 (5’-to-3’ DNA helicase) were the 
highest in Burkitt’s lymphoma and showed only minor 
differences among benign lymph nodes, MCL, FL and 
DLBCL. The level of TRF2 as well as PIF1 correlated 
positively with telomerase activity (77). These findings 
highlight a differential expression of TRF2 and PIF1 in 
NHL with an upregulation in Burkitt’s lymphoma. A study 
of our group found upregulation of genes that encode 
for different telomere associated proteins (TRF1, TRF2, 
POT1, TIN2, TPP1, RAP1 and DKC1) in MCL samples 
when compared to controls (80). Studies in larger cohorts 
would be desirable in order to investigate the clinical 
significance of telomere dysfunction in this entity.
3.3. Plasma cell disorders
Plasma cell disorders are characterized by the 
proliferation of a single clone of plasma cells in the bone 
marrow and by the detection of a monoclonal protein in 
blood and/or serum. These disorders may range from a 
phenotypically benign entity, monoclonal gammopathy 
of undetermined significance (MGUS), to symptomatic 
multiple myeloma (MM) with lytic bone lesions, bone 
marrow failure, and renal damage. Approximately 1% 
of individuals with MGUS evolve to MM per year (86). 
Recent advances in molecular cytogenetic, genomic, 
and proteomic studies of tumor cells and their normal 
counterparts have allowed for increased understanding 
of the pathogenesis of MM. They have also provided the 
basis for molecular prognostic classification, identified 
potential therapeutic targets, and improve patient 
outcome (87).
As known, MM is associated with considerable 
cytogenetic instability, involving translocations and 
additions or deletions of whole chromosomes. When 
Cottliar et al (88) studied telomere length measured 
by Terminal Restriction Fragments in patients with MM 
and MGUS, they observed a reduction in TL in MM 
patients, in agreement with other studies (89), as well as 
a significant increase in the occurrence of chromosome 
instability, a critical factor in the initiation and progression 
of human cancers (90). Simultaneously, Wu et al (89) 
have observed a very strong correlation between 
cytogenetic abnormalities and the presence of high 
telomerase activity levels and/or short TL. For instance, 
deletion of chromosome 13, a marker of poor prognosis, 
and duplication of chromosome 3, in which TERC gene 
is located, were strongly associated with both high 
telomerase activity and short TL. Given that MM patients 
with abnormal karyotypes have a worse prognosis than 
those with a normal pattern (91, 92) the association of 
abnormal karyotypes with telomere reduction supports 
the importance of this mechanism in the development 
and/or progression of the disease.
Xu et al (93) reported elevated telomerase 
activity in 78% of MM patients and all cases with plasma 
cell leukemia. However, telomerase levels were not 
elevated in MGUS. As shown in Table 1, studies of our 
group have found increased expression levels of TERT, 
in MM as well as in MGUS, providing the first evidence 
of a modification in the expression of telomerase gene 
in these entities (94). Interestingly, in both pathologies 
a similar pattern of TERT expression was observed, 
in which patients displaying the highest telomerase 
transcription levels had the shortest TLs. More recently, 
Diaz de la Guardia et al (95) using gene expression arrays 
have identified that TERT along with other 16 genes 
are directly involved in TL maintenance in MM cells. 
The expression levels of these genes were even higher 
than those in human embryonic stem cells and induced 
pluripotent stem cells, which have unlimited proliferation 
capacity.
The expression profile of shelterin genes in 
plasma cell disorders have been extensively studied by 
our group (Table 1) (94, 96, 97). Our findings showed 
increased expression of shelterin components in MM 
compared to MGUS. Among the six shelterin subunits, 
POT1 showed particular significance for being strongly 
associated with clinical features such as advanced 
clinical stages, high calcium and β2-microglobulin levels 
and the presence of bone lesions (96). Moreover, in 
multivariate analysis, POT1 expression was a significant 
independent prognostic factor for overall survival as well 
as the International Staging System. Thus, our findings 
suggest this gene as a useful prognostic factor in MM as 
well as a possible molecular target for new therapeutic 
approaches. Our group has also investigated a set of 
non-shelterin genes involved in essential processes such 
as replication (RPA1), DNA damage repair pathways 
(MRE11-RAD50-NBS) and stabilization of telomerase 
complex (DKC1). We observed, for the first time, a 
significant increase in the expression of all these genes 
along with an upregulation of TERT and reduced TL in 
MM compared with MGUS (97), providing new insights 
into the intricate mechanisms by which telomere-
associated proteins collaborate in the maintenance of 
plasma cells immortalization and suggesting a role for 
the upregulation of these genes in the progression of the 
disease. Nevertheless, further studies at the protein level 
are needed to confirm all these transcriptional changes.
As it was referred for CLL, recent studies have also 
evidenced altered expression of sno/scaRNAs, associated 
to the H/ACA RNP complex, in plasma cell disorders. For 
instance, Lopez-Corral et al (98) found overexpression 
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of SNORD25, SNORD27, SNORD30, and SNORD31 
in smoldering MM patients correlated with shorter time 
to progression to symptomatic disease. Furthermore, 
two different studies (99, 100) reported the upregulation 
of ACA11 (SCARNA22) in MM patients harboring the 
recurrent translocation t(4;14)(p16;q32) (101), associated 
to short survival in this pathology (87, 91). This scaRNA, 
located within intron 18-19 of the WHSC1 (Wolf-
Hirschhorn syndrome candidate 1) gene (also known 
as MMSET: multiple myeloma SET Domain Containing 
Protein), can suppress oxidative stress both in vitro and 
in vivo, facilitate cell proliferation and protect cells from 
the effects of chemotherapy, suggesting its importance 
in tumor development. In addition, Ronchetti et al (100) 
found a general pattern of down regulation of sno/
scaRNAs expression in MM and secondary plasma 
cell leukemia patients compared with a non-neoplastic 
counterpart, as well as a specific pattern of sno/scaRNAs 
associated to distinct molecular subtypes of MM. 
Particularly, upregulation of SNORD36C, SNORD63, 
SNORD95 and SNORA40 was observed in hyperdiploid 
MM cases, and a signature overexpressing members of 
SNORD115 and SNORD116 families, in patients showing 
low-to-moderate levels of the CCND1 (Cyclin D1) gene in 
the absence of any primary IGH (immunoglobulin heavy 
chain) translocation and hyperdiploid status. Overall, 
these findings add more complexity to the molecular 
heterogeneity of plasma cell disorders, constituting 
possible new prognostic biomarkers in these pathologies.
4. PERSPECTIVES
Telomerase has emerged as an attractive target 
for future cancer treatments since telomerase is the 
mechanisms employed by a vast majority of cancer cells 
to enable unlimited proliferation. Several strategies have 
been developed considering two main aspects. First, 
telomerase must be the main mechanism of telomere 
maintenance; second, normal somatic cells, with very low 
or no telomerase activity, would be unaffected as they 
have longer telomeres compared to telomerase-positive 
cancer cells. In this context, increasing knowledge on 
shelterin components and telomere-associated genes 
has brought insight into their specific role in the regulation 
of telomere structure and function. As seen in this review, 
different forms of cancer show unique expression profiles 
of telomere-associated genes. It would be interesting 
to investigate whether this heterogeneity defines a 
subgroup of patients that may be particularly sensitive to 
telomerase-targeted therapy.
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